NDA 220936, held by Nuvalent. Neladalkib.
As of Nov 22, 2026, NDA 220936 (Nelkarmi), held by Nuvalent, was first approved by FDA on Nov 17, 2026, with 1 approved supplement and 0 published complete response letters.
| Nov 17, 2026 | Original applicationNew molecular entity · Priority review | Approved | |
| Nov 17, 2026 | Supplement 1New molecular entity · Priority review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Nelkarmi150MG · tablet; oral | Neladalkib | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters